Stock Track | Vericel Soars 13% on Strong Q3 Earnings Beat and Raised Outlook

Stock Track11-06

Vericel Corporation (NASDAQ: VCEL) saw its stock price surge 13% in pre-market trading on Thursday following the release of its impressive third-quarter 2025 financial results. The biotechnology company significantly outperformed market expectations, demonstrating strong growth and improved profitability across key metrics.

The Q3 earnings report revealed several positive highlights. Vericel reported revenue of $67.5 million, handily beating the analyst estimate of $64.6 million. Earnings per share (EPS) came in at $0.10, surpassing the anticipated loss of $0.01 per share. The company's flagship product, MACI, saw its revenue grow by 25% to $55.7 million, driving overall growth. Profitability also improved significantly, with adjusted EBITDA reaching $17 million, representing a 25% margin.

Adding to the optimistic sentiment, Vericel provided a favorable full-year revenue outlook of $272-276 million, aligning well with current market estimates. The company also reaffirmed its expectations for MACI revenue growth in the low 20% range and maintained its gross margin guidance at 74%. With these strong results and positive future guidance, investors are showing confidence in Vericel's growth strategy and market position, driving the significant pre-market stock price increase.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172598718?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 23:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172598718","market":"hk","top_or_hot":-1,"title":"Stock Track | Vericel Soars 13% on Strong Q3 Earnings Beat and Raised Outlook","media":"Stock Track","content":"<p>Vericel Corporation (NASDAQ: VCEL) saw its stock price surge 13% in pre-market trading on Thursday following the release of its impressive third-quarter 2025 financial results. The biotechnology company significantly outperformed market expectations, demonstrating strong growth and improved profitability across key metrics.</p>\n\n<p>The Q3 earnings report revealed several positive highlights. Vericel reported revenue of $67.5 million, handily beating the analyst estimate of $64.6 million. Earnings per share (EPS) came in at $0.10, surpassing the anticipated loss of $0.01 per share. The company's flagship product, MACI, saw its revenue grow by 25% to $55.7 million, driving overall growth. Profitability also improved significantly, with adjusted EBITDA reaching $17 million, representing a 25% margin.</p>\n\n<p>Adding to the optimistic sentiment, Vericel provided a favorable full-year revenue outlook of $272-276 million, aligning well with current market estimates. The company also reaffirmed its expectations for MACI revenue growth in the low 20% range and maintained its gross margin guidance at 74%. With these strong results and positive future guidance, investors are showing confidence in Vericel's growth strategy and market position, driving the significant pre-market stock price increase.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Vericel Soars 13% on Strong Q3 Earnings Beat and Raised Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Vericel Soars 13% on Strong Q3 Earnings Beat and Raised Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-06 23:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vericel Corporation (NASDAQ: VCEL) saw its stock price surge 13% in pre-market trading on Thursday following the release of its impressive third-quarter 2025 financial results. The biotechnology company significantly outperformed market expectations, demonstrating strong growth and improved profitability across key metrics.</p>\n\n<p>The Q3 earnings report revealed several positive highlights. Vericel reported revenue of $67.5 million, handily beating the analyst estimate of $64.6 million. Earnings per share (EPS) came in at $0.10, surpassing the anticipated loss of $0.01 per share. The company's flagship product, MACI, saw its revenue grow by 25% to $55.7 million, driving overall growth. Profitability also improved significantly, with adjusted EBITDA reaching $17 million, representing a 25% margin.</p>\n\n<p>Adding to the optimistic sentiment, Vericel provided a favorable full-year revenue outlook of $272-276 million, aligning well with current market estimates. The company also reaffirmed its expectations for MACI revenue growth in the low 20% range and maintained its gross margin guidance at 74%. With these strong results and positive future guidance, investors are showing confidence in Vericel's growth strategy and market position, driving the significant pre-market stock price increase.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VCEL","symbol_name":"Vericel Corporation","start_time":0,"source_url":"","article_id":"1172598718","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172598718","pubTimestamp":1762444032,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Vericel Corporation (NASDAQ: VCEL) saw its stock price surge 13% in pre-market trading on Thursday following the release of its impressive third-quarter 2025 financial results. The biotechnology...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VCEL":"Vericel Corporation"},"translate_title":"股票追踪|Vericel因第三季度盈利强劲增长和前景上调而飙升13%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCEL":1},"content_text":"Vericel Corporation (NASDAQ: VCEL) saw its stock price surge 13% in pre-market trading on Thursday following the release of its impressive third-quarter 2025 financial results. The biotechnology company significantly outperformed market expectations, demonstrating strong growth and improved profitability across key metrics.\nThe Q3 earnings report revealed several positive highlights. Vericel reported revenue of $67.5 million, handily beating the analyst estimate of $64.6 million. Earnings per share (EPS) came in at $0.10, surpassing the anticipated loss of $0.01 per share. The company's flagship product, MACI, saw its revenue grow by 25% to $55.7 million, driving overall growth. Profitability also improved significantly, with adjusted EBITDA reaching $17 million, representing a 25% margin.\nAdding to the optimistic sentiment, Vericel provided a favorable full-year revenue outlook of $272-276 million, aligning well with current market estimates. The company also reaffirmed its expectations for MACI revenue growth in the low 20% range and maintained its gross margin guidance at 74%. With these strong results and positive future guidance, investors are showing confidence in Vericel's growth strategy and market position, driving the significant pre-market stock price increase.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172598718","isCrawlerRequest":true}